SurModics (SRDX) Tops Q3 EPS by 11c, Beats on Revenues; Offers FY Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts SRDX Hot Sheet
Join SI Premium – FREE
SurModics (NASDAQ: SRDX) reported Q3 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $15.98 million.
- FDA approves 446 patient SurVeil® DCB Pivotal Study
- Total Revenue of $17.8 Million
- EPS of $0.05, Non-GAAP EPS of $0.09
- Increases financial outlook for fiscal 2017
GUIDANCE:
SurModics sees FY2017 EPS of $0.29-$0.39, versus the consensus of $0.19. SurModics sees FY2017 revenue of $70-72 million, versus the consensus of $67.59 million.
For earnings history and earnings-related data on SurModics (SRDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- AXIL Brands (AXIL) Reports Q1 EPS of $0.05
- Clarivate completes $600M sale of life sciences unit to Altaris
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
